Pharma&Biotech
Superior performance comes from alignment at every level
Integrate and innovate with Lonza’s cytotoxic manufacturing team Watch the pieces fall into place when you work with the experts. Recent innovations in production of highly potent active pharmaceutical ingredients (APIs) have improved development for important treatments in the area of oncology. Lonza recently invested CHF 24 million in the expansion of its cytotoxic manufacturing facilities to include multi-kilogram capacity for clinical and commercial scale production.
[email protected] North America +1 201 316 9200 Europe + 41 61 316 81 11
2011_08_CEN_Rackwheel.indd 1
Lonza ofers excellence in cytotoxic production with: – Superior performance – Swiss quality and safety standards – Appropriate containment and product segregation – Training and development expertise
www.lonza.com 09.08.2011 17:00:34
